Canaccord Genuity analyst initiated coverage with a Hold rating on Amgen yesterday and set a price target of $366.00. The company’s shares closed yesterday at $344.86. Claim 30% ...

We recently compiled a list of the 10 Most Undervalued Dow Stocks to Buy Now. Amgen Inc. is one of the most undervalued ...

A former Amgen Inc. employee filed a proposed class action challenging the biotechnology company’s practice of charging ...

THOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of David M. Reese, M.D., executive vice president and Chief Technology Officer, effective June ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

If you are wondering whether Amgen’s recent share price puts it on sale or at a premium, and what that really means for your ...

Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

Sixth batch under OASES initiative also features Boehringer Ingelheim, Hengrui and Haya, with Didi and AutoFlight joining ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. New data from a mid-stage study of an Amgen obesity drug showed that it ...

Global drug maker Pfizer (PFE) and biotech firm Amgen (AMGN), each valued at over HK$1T ($153B), are among 22 strategic ...